Is first eye cataract surgery cost effective?

Article

First eye cataract surgery is probably more cost-effective over a patient's remaining lifetime than if they have no surgery at all.

First eye cataract surgery is probably more cost-effective over a patient's remaining lifetime than if they have no surgery at all, according to a study published in the December issue of the British Journal of Ophthalmology.

Tracey Sach and colleagues from the University of East Anglia, UK evaluated the cost-effectiveness of first eye cataract surgery compared with no surgery from a health service and personal social services perspective. A sample of 306 women aged 70 years or older with bilateral cataracts were randomized to cataract surgery (expedited) or control (routine 12-month wait for surgery).

The operated group cost a mean £2,004 (approx. €2,800) more than the control group over one year. However, they experienced an average 0.456 fewer falls, an incremental cost per fall prevented of £4,390 (approx. €6,150). The mean gain in quality of life years (QALYs) per patient was 0.056. The incremental cost-utility ratio was £35,704 (approx. €50,000), above the currently accepted UK threshold level of willingness to pay per QALY of £30,000 (approx. €42,000). However, in an analysis modelling costs and benefits over a patients' expected lifetime, the incremental cost per QALY was £13,172 (approx. €18,500) under conservative assumptions.

According to the researchers, although first eye cataract surgery was not cost-effective over the trial period, it is probably more cost-effective over a patients' remaining lifetime, than if they had no surgery at all.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.